Patients with CABG History and new N-ST ACS: Routine Invasive Strategy?

Multiple studies support the use of an early invasive approach in high risk patients with non-ST elevation acute coronary syndrome (NST ACS). This benefit of an invasive strategy over the expected management has been shown in randomized studies and meta-analysis. Patients with a history of cardiac artery bypass graft (CABG) represent approximately 10% of ACS cases. This is a high risk subgroup because of their comorbidities and older age. However, these patients have often been excluded from the large studies assessing treatment strategies, such as the TIMI IIIB, REISC II and RITA 3.

El Impella otorga seguridad en la ATC del TCI no protegido de alto riesgo

Observational data show ACS + CABG patients receive fewer diagnostic studies or angioplasty procedures. This reflects higher risks associated with coronary angiograms, seeing the larger number of vessels to be assessed, the variable location of grafts and the scarce information on prior surgical procedures. The same happens when assessing revascularization, with native disease progression and the difficulty inherent to graft angioplasty, given embolization risk. 

Prior subgroup studies, with meta-analysis data, have shown patients at very high risk, of advanced age and those with chronic kidney disease, do not benefit from a routine invasive approach.  

The aim of this study was to determine whether a routine invasive approach is superior to a selective invasive or conservative approach, conducting a systematic review and meta-analysis in patients with CABG and NST ACS.

Read also: Low-Flow Aortic Stenosis: What is the Value of Valve Calcification in its Interpretation?

It included 19 studies (including TACTICS-TIMI, CABG-ACS, LIPSIA-NSTEMI), with 12 eligible studies after exclusions, with a total 897 patients with NST ACS randomized to routine invasive approach (n=477) or selective/conservative (n=420). 97.4% of routine approach patients, 45.4% of the conservative, and 19.3% in the selective group received in-hospital angiographies. 

When looking at mortality, there was high heterogeneity, with average 18.7% morality for the invasive strategy and 12.9% for the conservative. There was no reduction in all-cause mortality (RR 1.12; 95% CI 0.97–1.29; P = .12), and sensitivity analysis excluding elderly patients showed the same results. 

As regards cardiac mortality, 25.2% of patients in the invasive strategy group presented this outcome vs 19.3% in the conservative management, with no significant changes in cardiac mortality risk between the strategies (RR 1.05; 95% CI 0.70–1.58; P = .81).

Read also: BIONYX: Onyx vs. Orsiro At 5 Years.

When looking at acute MI, the invasive strategy patients presented 15.5% vs el 16.4%, with no significant differences (RR 0.90; 95% CI 0.65–1.23, P = .49). Some patients presented new cardiac rehospitalization, with no changes for the invasive strategy patients (19.2%) vs conservative patients (17.7%) (RR 1.05; 95% CI 0.78–1.40, P = .77).   

Conclusions

This meta-analysis of randomized studies on routine invasive strategies in patients with NST ACS and CABG (high risk subgroup) showed a routine invasive approach did not modify all-cause mortality, cardiovascular mortality, acute MI hospitalizations or cardiac hospitalizations, suggesting a lack of benefit. However, specific randomized studies are needed to confirm these findings. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: a meta-analysis of invasive vs. conservative management.

Reference: Matthew Kelham, Rohan Vyas, Rohini Ramaseshan, Krishnaraj Rathod, Robbert J de Winter, Ruben W de Winter, Bjorn Bendz, Holger Thiele, Geir Hirlekar, Nuccia Morici, Aung Myat, Lampros K Michalis, Juan Sanchis, Vijay Kunadian, Colin Berry, Anthony Mathur, Daniel A Jones, Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: a meta-analysis of invasive vs. conservative management, European Heart Journal, 2024;, ehae245, https://doi.org/10.1093/eurheartj/ehae245.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....